📊 VTVT Key Takeaways
Is vTv Therapeutics Inc. (VTVT) a Good Investment?
vTv Therapeutics faces critical fundamental deterioration with complete revenue collapse (-100% YoY to $0.00) and sustained operating losses (-$32.8M) despite a strong balance sheet. While $88.9M cash and minimal debt (0.02x leverage) provide near-term runway (~3.5 years at current burn), the absence of revenue generation combined with negative ROE/ROA (-41.9% / -30.0%) and -$25.3M operating cash burn indicates a broken business model requiring dramatic operational recovery or strategic restructuring.
Why Buy vTv Therapeutics Inc. Stock? VTVT Key Strengths
- Fortress balance sheet: $88.9M cash with only $1.3M long-term debt and 0.02x debt-to-equity ratio
- Strong liquidity position: 13.54x current ratio provides financial flexibility for operations and R&D
- Positive stockholders' equity of $64.4M creates buffer against balance sheet deterioration
VTVT Stock Risks: vTv Therapeutics Inc. Investment Risks
- Complete revenue collapse: Zero revenue with -100% YoY decline indicates loss of primary revenue source or product failure
- Severe operating losses: -$32.8M operating income and -$27.0M net loss with negative ROE/ROA (-41.9%/-30.0%) show fundamental unprofitability
- Negative operating cash flow: -$25.3M FCF burn rate unsustainable long-term; at current rate, cash depleted in ~3.5 years without revenue recovery
- No clear revenue catalyst: Absence of sales combined with ongoing losses suggests business model failure or incomplete restructuring
Key Metrics to Watch
- Revenue regeneration timeline and magnitude from existing or new programs
- Quarterly operating cash burn rate trend (acceleration/deceleration)
- Cash runway remaining and covenant compliance with remaining liabilities
- Form 4 insider buying activity and management commentary on path to profitability
vTv Therapeutics Inc. (VTVT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 13.54x current ratio provides a solid financial cushion.
VTVT Profit Margin, ROE & Profitability Analysis
VTVT vs Healthcare Sector: How vTv Therapeutics Inc. Compares
How vTv Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is vTv Therapeutics Inc. Stock Overvalued? VTVT Valuation Analysis 2026
Based on fundamental analysis, vTv Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
vTv Therapeutics Inc. Balance Sheet: VTVT Debt, Cash & Liquidity
VTVT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: vTv Therapeutics Inc.'s revenue has declined by 84% over the 5-year period, indicating business contraction.
VTVT Revenue Growth, EPS Growth & YoY Performance
VTVT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$4.8M | N/A |
| Q2 2025 | N/A | -$5.2M | N/A |
| Q1 2025 | N/A | -$4.9M | N/A |
| Q3 2024 | N/A | -$4.8M | N/A |
| Q2 2024 | N/A | -$5.2M | N/A |
| Q1 2024 | N/A | -$4.5M | N/A |
| Q3 2023 | N/A | -$4.3M | N/A |
| Q2 2023 | N/A | -$3.2M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
vTv Therapeutics Inc. Dividends, Buybacks & Capital Allocation
VTVT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for vTv Therapeutics Inc. (CIK: 0001641489)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VTVT
What is the AI rating for VTVT?
vTv Therapeutics Inc. (VTVT) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VTVT's key strengths?
Claude: Fortress balance sheet: $88.9M cash with only $1.3M long-term debt and 0.02x debt-to-equity ratio. Strong liquidity position: 13.54x current ratio provides financial flexibility for operations and R&D.
What are the risks of investing in VTVT?
Claude: Complete revenue collapse: Zero revenue with -100% YoY decline indicates loss of primary revenue source or product failure. Severe operating losses: -$32.8M operating income and -$27.0M net loss with negative ROE/ROA (-41.9%/-30.0%) show fundamental unprofitability.
What is VTVT's revenue and growth?
vTv Therapeutics Inc. reported revenue of $0.0.
Does VTVT pay dividends?
vTv Therapeutics Inc. does not currently pay dividends.
Where can I find VTVT SEC filings?
Official SEC filings for vTv Therapeutics Inc. (CIK: 0001641489) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VTVT's EPS?
vTv Therapeutics Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VTVT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, vTv Therapeutics Inc. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VTVT stock overvalued or undervalued?
Valuation metrics for VTVT: ROE of -41.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VTVT stock in 2026?
Our dual AI analysis gives vTv Therapeutics Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VTVT's free cash flow?
vTv Therapeutics Inc.'s operating cash flow is $-25.3M, with capital expenditures of $0.0.
How does VTVT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -41.9% (avg: 15%), current ratio 13.54 (avg: 2).